Melaena following use of the cholinesterase inhibitor rivastigmine

Clinical Drug Investigation

Volumn 25, Issue 3, 2005, Pages 215-217

  Gareri, Pietro ^a,b   Gallelli, Luca ^a   Ferreri Ibbadu, Guido ^a   Lacava, Roberta ^b   Russo, Emilio ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Operative Unit 'Elderly Health Care   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE INHIBITOR; ESOMEPRAZOLE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; OMEPRAZOLE; RIVASTIGMINE;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; ERYTHROCYTE COUNT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROSCOPY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MELENA; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; THROMBOCYTE COUNT; VOMITING;

EID: 16244401933     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525030-00008     Document Type: Article

References (13)

1. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998 Jul-Aug; 20 (4): 634-47
2. Desai A, Grossberg G. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert Opin Pharmacother 2001 Apr; 2 (4): 653-66
3. Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318 (7184): 633-8
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
5. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; 127: 45-63
6. Bilikiewicz A, Opala G, Podemski R, et al. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Med Sci Monit 2002; 8: 9-15
7. Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, et al. Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer's disease over a six-month period. Rev Neurol 2003; 36: 421-4
8. Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002; 17: 81-5
9. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003; 65: 103-31
10. Geibel JP, Wagner CA, Caroppo R, et al. The stomach divalent ion-sensing receptor scar is a modulator of gastric acid secretion. J Biol Chem 2001; 276: 39549-52
11. Efendiev VM, Kasumov NA, Kiazimov AK, et al. Vagotomy in the treatment of bleeding reflux-esophagitis and gastroduodenal bleedings. Khirurgiia (Mosk) 2004; 6: 24-6
12. Lindberg P, Brandstrom A, Wallmark B, et al. Omeprazole: the first proton pump inhibitor. Med Res Rev 1990; 10: 1-54
13. Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 1998; 4: 17-36